Desjardins Global Asset Management Inc. Reduces Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Desjardins Global Asset Management Inc. trimmed its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 42.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,724 shares of the medical equipment provider’s stock after selling 1,293 shares during the quarter. Desjardins Global Asset Management Inc.’s holdings in Intuitive Surgical were worth $582,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. OFI Invest Asset Management purchased a new stake in shares of Intuitive Surgical in the third quarter valued at about $25,000. Baystate Wealth Management LLC raised its position in shares of Intuitive Surgical by 150.0% during the 4th quarter. Baystate Wealth Management LLC now owns 75 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 45 shares during the period. Headinvest LLC purchased a new stake in shares of Intuitive Surgical during the 3rd quarter valued at approximately $28,000. Stone House Investment Management LLC raised its position in shares of Intuitive Surgical by 100.0% during the 3rd quarter. Stone House Investment Management LLC now owns 100 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 50 shares during the period. Finally, Householder Group Estate & Retirement Specialist LLC acquired a new stake in Intuitive Surgical during the third quarter worth $30,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Alan J. Levy sold 2,000 shares of the company’s stock in a transaction on Friday, January 26th. The stock was sold at an average price of $370.20, for a total value of $740,400.00. Following the completion of the transaction, the director now directly owns 25,319 shares in the company, valued at $9,373,093.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Intuitive Surgical news, VP Marshall Mohr sold 108,790 shares of the business’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the completion of the sale, the vice president now owns 26,877 shares of the company’s stock, valued at $10,349,795.16. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Alan J. Levy sold 2,000 shares of Intuitive Surgical stock in a transaction dated Friday, January 26th. The shares were sold at an average price of $370.20, for a total value of $740,400.00. Following the completion of the transaction, the director now directly owns 25,319 shares in the company, valued at $9,373,093.80. The disclosure for this sale can be found here. Insiders have sold a total of 248,418 shares of company stock valued at $95,927,097 in the last quarter. 0.90% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on ISRG shares. Truist Financial upped their price target on Intuitive Surgical from $390.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, January 24th. Citigroup boosted their price target on shares of Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Raymond James increased their price objective on shares of Intuitive Surgical from $372.00 to $435.00 and gave the stock an “outperform” rating in a research report on Thursday, January 25th. Mizuho boosted their target price on Intuitive Surgical from $350.00 to $390.00 and gave the company a “neutral” rating in a research report on Thursday, January 25th. Finally, Piper Sandler lifted their price objective on Intuitive Surgical from $325.00 to $425.00 and gave the company an “overweight” rating in a research note on Wednesday, January 24th. Five analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and a consensus target price of $375.70.

Intuitive Surgical Stock Performance

Intuitive Surgical stock opened at $374.17 on Thursday. Intuitive Surgical, Inc. has a one year low of $254.85 and a one year high of $403.76. The business has a fifty day moving average of $387.56 and a two-hundred day moving average of $342.39. The company has a market cap of $132.62 billion, a P/E ratio of 74.39, a price-to-earnings-growth ratio of 5.88 and a beta of 1.36.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Tuesday, January 23rd. The medical equipment provider reported $1.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.48 by $0.12. The firm had revenue of $1.93 billion for the quarter, compared to analyst estimates of $1.89 billion. Intuitive Surgical had a return on equity of 13.11% and a net margin of 25.24%. Intuitive Surgical’s revenue was up 16.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.91 EPS. Sell-side analysts predict that Intuitive Surgical, Inc. will post 4.93 EPS for the current year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.